Technology
Health
Biotechnology

Synlogic

$7.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.13 (-1.81%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Synlogic and other stocks, options, ETFs, and crypto commission-free!

About SYBX

Synlogic, Inc. Common Stock, also called Synlogic, is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. Read More It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Employees
74
Headquarters
Cambridge, Massachusetts
Founded
2017
Market Cap
179.24M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
152.04K
High Today
$7.35
Low Today
$6.90
Open Price
$7.19
Volume
170.23K
52 Week High
$14.59
52 Week Low
$5.75

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Cancer Prevention
Pharmaceutical
2015 IPO

SYBX News

BenzingaJul 15

Synlogic Shares Positive Data From SYNB1618 Study

41

SYBX Earnings

-$0.74
-$0.64
-$0.53
-$0.43
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours

More SYBX News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.